阿柏西普
脉络膜新生血管
血管抑制剂
医学
黄斑变性
血管内皮生长因子
贝伐单抗
遗传增强
垂直波分
眼科
糖尿病性视网膜病变
新生血管
人口
血管生成
哌加他尼
PEDF公司
视网膜
外科
内科学
血管内皮生长因子受体
化疗
内分泌学
生物
基因
糖尿病
生物化学
环境卫生
作者
Samaneh Toutounchian,Naser Ahmadbeigi,Vahid Mansouri
出处
期刊:Journal of Ocular Pharmacology and Therapeutics
[Mary Ann Liebert]
日期:2022-10-01
卷期号:38 (8): 529-548
标识
DOI:10.1089/jop.2022.0022
摘要
Neovascularization in ocular vessels causes a major disease burden. The most common causes of choroidal neovascularization (CNV) are age-related macular degeneration and diabetic retinopathy, which are the leading causes of irreversible vision loss in the adult population. Vascular endothelial growth factor (VEGF) is critical for the formation of new vessels and is the main regulator in ocular angiogenesis and vascular permeability through its receptors. Laser therapy and antiangiogenic factors have been used for CNV treatment. Bevacizumab, ranibizumab, and aflibercept are commonly used anti-VEGF agents; however, high costs and the need for frequent intraocular injections are major drawbacks of anti-VEGF drugs. Gene therapy, given the potency of one-time treatment and no need for frequent injections offers the real possibility of such a lasting treatment, with fewer adverse effects and higher patient quality of life. Herein, we reviewed the role of gene therapy in the CNV treatment. In addition, we discuss the advantages and challenges of current treatments compared with gene therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI